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AbstrACt
Introduction In Australia, general practitioners usually 
are the first point of contact for patients with non-urgent 
medical conditions. Appropriate and efficient utilisation of 
pathology tests by general practitioners forms a key part 
of diagnosis and monitoring. However overutilisationand 
underutilisation of pathology tests have been reported 
across several tests and conditions, despite evidence-
based guidelines outlining best practice in pathology 
testing. There are a limited number of studies evaluating 
the impact of these guidelines on pathology testing in 
general practice. The aim of our quantitative observational 
study is to define how pathology tests are used in general 
practice and investigate how test ordering practices align 
with evidence-based pathology guidelines.
Methods and analysis Access to non-identifiable 
patient data will be obtained through electronic health 
records from general practices across three primary 
health networks in Victoria, Australia. Numbers and 
characteristics of patients, general practices, encounters, 
pathology tests and problems managed over time will be 
described. Overall rates of encounters and tests, alongside 
more detailed investigation between subcategories 
(encounter year, patient’s age, gender, and location and 
general practice size), will also be undertaken. To evaluate 
how general practitioner test ordering coincides with 
evidence-based guidelines, five key candidate indicators 
will be investigated: full blood counts for patients on 
clozapine medication; international normalised ratio 
measurements for patients on warfarin medication; 
glycated haemoglobin testing for monitoring patients with 
diabetes; vitamin D testing; and thyroid function testing.
Ethics and dissemination Ethics clearance to collect 
data from general practice facilities has been obtained by 
the data provider from the RACGP National Research and 
Evaluation Ethics Committee (NREEC 17–008). Approval for 
the research group to use these data has been obtained 
from Macquarie University (5201700872). This study 
is funded by the Australian Government Department of 
Health Quality Use of Pathology Program (Agreement ID: 
4-2QFVW4M). Findings will be reported to the Department 
of Health and disseminated in peer-reviewed academic 
journals and presentations (national and international 
conferences, industry forums).
IntroduCtIon  
In Australia, general practitioners (GPs) are 
usually the first point of contact for patients 
with non-emergency health problems. They 
play an important role in the early detec-
tion, prevention (including shared-care 
arrangements) and treatment of disease.1 
Pathology tests are a key part of general prac-
tice assisting GPs in diagnosing, screening, 
treating and monitoring diseases. The past 
decade has seen an increase in both visits to 
and problems managed by GPs in Australia, 
resulting in an estimated 24.2 million addi-
tional pathology tests being ordered in 2015–
2016 compared with 2006–2007.2 
Appropriate and timely utilisation of 
pathology tests can improve the quality and 
outcome of patient care. However, both over-
utilisation and underutilisation of pathology 
tests have been frequently observed in a 
strengths and limitations of this study
 ► The study population will be drawn from a large re-
gion in Victoria, Australia, and is expected to contain 
a large sample population (data from approximately 
350 general practices), along with a large number 
of demographic variables (eg, region, gender, age).
 ► Electronic health records contain a vast amount of 
information on patients, allowing us to control for 
potential interacting or predictive variables on pa-
tient outcomes using statistical modelling.
 ► Some electronic health record fields may not be 
completely standardised across practices and could 
contain inconsistencies and missing information, 
which may limit the volume of data that can be ex-
tracted and analysed.
 ► Some medications being investigated in this study 
may be prescribed and/or monitored by specialists, 
which may result in cases being missed.
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range of clinical scenarios.3 4 Several guidelines have been 
established to encourage better utilisation of pathology 
tests among GPs across Australia, USA, Canada and the 
UK. These include initiatives such as Choosing Wisely5, 
National Institute for Health and Clinical Excellence (NICE)6 
and Royal Australian College of General Practitioners (RACGP) 
Guidelines for preventative activities in general practice.7 
Currently, there is little evidence on how test ordering 
practices by GPs align with these recommendations and 
guidelines in Australia, and elsewhere. A survey of 600 US 
doctors revealed only 21% of doctors were familiar with 
the Choosing Wisely campaign. However, doctors aware 
of the campaign had a lower proportion of unnecessary 
pathology testing.8 In Australia, increased awareness of 
best-practice in vitamin D test ordering is reported to 
have contributed to a reduction in healthcare costs and 
potentially unnecessary tests.9 Considering the impor-
tance of pathology testing for managing diseases, a better 
understanding of how pathology testing by GPs coincides 
with evidence-based guidelines will be invaluable for the 
success of management and disease-prevention strategies.
Until recently, the survey-based Bettering the Evaluation 
and Care of Health (BEACH) study provided the most 
comprehensive data on Australian GP activity.2 However, 
its cross-sectional design prevented it from reporting 
longitudinal patient level changes and outcomes. The 
BEACH study was discontinued in 2016 and has since 
left a gap in our understanding of GP activity, particu-
larly in relation to pathology test ordering. The exten-
sive use of computers by Australian GPs has prompted 
interest in the use of electronic health record (EHR) 
data as a research source for monitoring the quality of GP 
services, and has led to research and publications based 
on EHR data.10 The Australian Department of Health 
funded NPS Medicinewise MedicinesInsight data set 
contains a national collection of EHRs from 650 prac-
tices covering over 3300 GPs and nearly 3.6 million active 
patients.11This data set has been used in several popula-
tion health research projects and has demonstrated the 
value of EHR data in research.12 This study will use EHR 
data from the POLAR Data Space, containing de-iden-
tified data from consenting general practices collected 
on behalf of Australian primary health networks (PHNs) 
from approximately 350 practices. POLAR Data Space 
has added measures to ensure robust and accurate data, 
and implements standardised terminologies to make the 
data more approachable for research use. This study, 
undertaken in collaboration with POLAR Data Space 
Research Consortia and its associated PHNs, will facilitate 
a comprehensive analysis of general practice activity and 
its relationship to pathology testing in Australia through 
EHR data.
objectives
The objectives of this study are to:
1. Describe general practice activity and characteristics 
of pathology test ordering based on electronic health 
record data.
2. Investigate compliance with evidence-based guidelines 
to determine the appropriateness and quality use of 
pathology in general practice.
MEthods And AnAlysEs
study design
A retrospective observational study of Australian general 
practice health records and pathology testing data. The 
study will run for a period of approximately 2 years span-
ning from early 2018 to late 2019.
data source
Data to be used in this study will be provided by the 
POLAR Data Space.10 POLAR Data Space collects 
de-identified data from consenting general practices on 
behalf of Australian PHNs including Gippsland, Eastern 
Melbourne and South Eastern Melbourne PHNs. Data 
are extracted from approximately 350 practices in urban 
and rural regions in Victoria, Australia. The primary 
purpose of the data collection is to provide information 
to improve patient care at the practice level and popu-
lation health initiatives at the PHN level. POLAR Data 
Space has ethics approval for the collection, storage and 
de-identification of the data, which it makes available for 
approved research governed by the involved PHNs.
The data source will include pooled general prac-
tice patient data extracted from Best Practice, Medical 
Director and Zedmed EHRs. Data will include de-identi-
fied demographic information about patients and general 
practices, as well as visit records (diagnosis, past history, 
medications) and pathology test records (test name and 
result). Both historical and current information about 
patients will be acquired, providing a longitudinal record. 
It is expected that the data will span a period of over a 
decade, from early 2000s to early 2018.
study population
The study population will consist of all patients who visited 
any of the general practices included in the study and had 
their visit recorded in the practices’ EHR software.
Variables
The following criteria will be adopted to accurately 
describe general practice activity and ensure data quality: 
(i) a patient will be distinguished by a unique (non-iden-
tifiable) patient code recorded within a general practice 
and included if determined to be an active patient (ie, 
has visited the GP three or more times in the past 2 years, 
not deceased); (ii) an encounter (ie, consultation, visit) 
will be defined as a patient visit recorded by a doctor or 
nurse during which an action (eg, consultation, prescrip-
tion) is performed, and will be identified through a vari-
able indicating the visit type (eg, surgery, administrative, 
phone call); (iii) a pathology test will be defined as either 
a panel of interrelated tests (eg, full blood count) or an 
individual test (eg, troponin test); (iv) where possible, 
standardised records such as Logical Observation Iden-
tifiers Names and Codes (LOINC) and Systematised 
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Nomenclature of Medicine (SNOMED) terminologies 
will be prioritised to identify variables; otherwise, free-text 
data will be searched for terms of interest (eg, ‘diabetes’ 
or its abbreviated forms in the diagnosis field, excluding 
‘not diabetes’).
Analyses
Data examination and analysis will be performed using 
Stata/MP V.15.1 (StataCorp). The methods outlined in 
this protocol are structured according to the Strength-
ening the Reporting of Observational Studies in Epide-
miology checklist of items to be included in observational 
studies.13
Characteristics of general practice activity and pathology testing
In line with objective 1 of this study, we will analyse and 
describe Australian general practice characteristics 
and activity. These characteristics can subsequently be 
compared with reports on national demographics and 
healthcare statistics, such as Australian Institute of Health 
and Welfare’s annual reports.
Sample population characteristics will be reported. 
This will include describing the characteristics of patients, 
general practices, encounters, tests and problems 
managed across time. Subsequent analyses will describe 
overall median rates of encounters and tests, along-
side more detailed investigation between subcategories 
(encounter year, patient’s age, gender and postcode and 
number of active general practitioners in practice) using 
the following indicators: encounters per patient per year 
and tests per encounter.
The differences between subcategories will be further 
described as incidence rate ratios by generalised linear 
modelling (Poisson or negative binomial, whichever is 
appropriate).
Best practice guidelines-based analyses
In line with objective 2 of this study, we will describe the 
extent to which pathology ordering practices among 
Australian GPs aligns with evidence-based pathology 
testing guidelines. Five initial candidate indicators have 
been identified for analyses.
Monitoring patients on clozapine medication
Rationale
Clozapine is a highly effective antipsychotic drug that 
is used for managing chronic schizophrenia. However, 
clozapine use can result in neutropenia in nearly 2% 
of patients, and agranulocytosis in 1%14, warranting 
close monitoring of patients taking clozapine. Although 
clozapine is prescribed by specialists, monitoring is more 
frequently managed by GPs through shared-care arrange-
ments.15 After 18 weeks of initiation and monitoring 
under a specialist, GPs can also prescribe clozapine. 
Australian guidelines recommend patients on clozapine 
medication have blood tests for white blood cell and 
neutrophil counts weekly for the first 18 weeks of initia-
tion, and monthly thereafter.16 17 Furthermore, a patient 
cannot obtain clozapine from the pharmacist without a 
recent blood test. Currently, the state of monitoring for 
patients on clozapine medication is not known.
Analysis
The study population will be patients who are being 
prescribed clozapine by the GP (and therefore also need 
to be monitored). The time frame will include records 
after the first entry of the prescription into the EHR soft-
ware, and before medication is discontinued (or patient 
is deceased or is no longer an active patient). The demo-
graphic characteristics of patients on clozapine medi-
cation as well as number of full blood counts for these 
patients will be described overall, by patient gender, age 
and location, general practice size and year of test. The 
number of full blood counts per patient per year will 
also be described overall and by the demographic char-
acteristics, by counting the number of full blood count 
tests conducted for each patient on clozapine medica-
tion for each available year. Subsequently, the median 
number of full blood count tests per patient per year will 
be calculated, with the inter-quartile range. For patients 
who undergo more than one test, the time between tests 
will be determined. Subsequently, median time between 
tests will be calculated, with the inter-quartile range. As 
clozapine may also be prescribed by specialists, it may not 
be possible to determine when the medication was initi-
ated through the EHR software. Consequently, it may not 
be possible to differentiate patients who require weekly 
tests from patients who require monthly tests. Nonethe-
less, it is expected patients on clozapine medication will 
have at least one full blood count test within approxi-
mately 4 to 6 weeks of a prior test; which will indicate 
compliance with guidelines.
Measuring international normalised ratio levels for patients on 
warfarin medication
Rationale
Warfarin is a highly effective and widely used anticoag-
ulant in Australia. However, it is also one of the most 
common causes of prescribed medication-related 
mortality, due to its risk of causing bleeding.18 Best prac-
tice guidelines recommend that the initiation of warfarin 
medication should be accompanied by frequent Inter-
national Normalised Ratio (INR) measurements until 
a stable therapeutic range is reached. After INR levels 
are stable, testing frequency should be once every 4 to 
6 weeks unless a change (eg, initiation of another medi-
cation) that can affect INR levels occurs.19 20 Failure to 
correct INR levels is associated with increased mortality.21
Analysis
The sample population will be patients with a warfarin 
prescription. Only data entered after the first instance 
the prescription is recorded in the GP’s computer and 
before the patient permanently stops the medication (or 
death) will be considered for analysis. As the pathology 
test frequency and repeat interval requirements for 
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patients treated with warfarin are similar to the require-
ments for clozapine, similar reporting standards will be 
used. As with clozapine medication, it may not be possible 
to differentiate patients who are initiating warfarin medi-
cation from those who have reached stable INR levels. 
Despite this, based on best practice guidelines, it is 
expected that patients on warfarin medication will have at 
least one INR measurement approximately within 4 weeks 
of a prior measurement, which will be the criteria used to 
determine compliance with guidelines.
Glycated haemoglobin testing for management of patients with 
diabetes
Rationale
It is estimated that over one million Australians are 
diagnosed with diabetes, 85% of whom have type 2 
diabetes.22 Poor management of diabetes can lead to a 
range of complications, including cardiovascular and 
renal diseases and retinopathy.23 Best practice guidelines 
recommend recurrent glycated haemoglobin (HbA1c) 
testing in at least half-yearly intervals for patients with 
diabetes.24 HbA1c levels are a good indicator of long-
term blood glucose control over the previous 8–12 weeks. 
Uncontrolled glucose leading to high HbA1c levels may 
indicate increased risk of diabetes-related complications. 
As such, undertesting may be associated with failure to 
identify complications.
Analysis
The sample population will be patients diagnosed with 
type 2 diabetes. Only data after the diagnosis being 
recorded and before death will be included. The anal-
yses will be conducted and reported in a similar structure 
as outlined previously for clozapine and warfarin medi-
cation pathology testing guidelines. Based on the best 
practice guidelines, it is expected that a minimum of two 
HbA1c tests will be conducted in a year for patients diag-
nosed with diabetes.
Frequency of vitamin D testing
Rationale
A study on vitamin D testing found a considerable 
number of potentially unnecessary vitamin D tests 
ordered by Australian GPs.25 This has led to changes in 
funding programmes and the establishment of guide-
lines, suggesting only patients at risk of complications 
that may arise due to low vitamin D levels (eg, pregnant 
women, older patients at risk of falls, patients with osteo-
porosis) should be tested.26 Ultimately, an overall reduc-
tion of vitamin D tests was observed9; however, studies 
on whether the tests are being ordered according to the 
guidelines are limited.27
Analysis
To understand if vitamin D tests are being ordered 
according to guidelines, population and demographic 
characteristics associated with higher vitamin D testing 
will be investigated. The sample population will be all 
patients from which patients who had a vitamin D test 
will be identified and flagged (as the outcome variable). 
Univariate and multivariate logistic regression models 
will be fitted to identify any variation in vitamin D testing 
by the demographic characteristics of patients, diagnoses 
and general practices. Differences will be reported as ORs 
and their 95% confidence intervals. Descriptive charac-
teristics (patient’s gender, age, and location, general 
practice’s size and year of test) of the sample popula-
tion will also be described. To obtain an understanding 
of the reasons for vitamin D testing, other tests ordered 
simultaneously will be identified and examined, as well as 
preceding medication prescriptions and diagnoses.
Thyroid function tests
Rationale
Thyroid dysfunction can occur due to overutlisation 
or underfunction of the thyroid gland, and can lead to 
cardiovascular diseases or subclinical hypothyroidism 
(remains asymptomatic).28 Guidelines recommend 
assessing thyroid dysfunction by initial thyroid-stimu-
lating hormone (TSH) tests, which may be followed up 
by free triiodothyronine (fT3) and free thyroxine (fT4) 
tests to assist with diagnosis if an abnormal TSH result is 
observed.29 Otherwise, fT3 and fT4 tests are not recom-
mended without a prior TSH test. In Australia, there 
are currently no screening guidelines for when and how 
frequently TSH tests should be conducted among adults. 
The benefit of screening for thyroid disease, or even 
treating subclinical hypothyroidism, remains uncertain.30 
It would be valuable to understand the demographics for 
and frequency of TSH test ordering by Australian GPs.
Analysis
To describe thyroid function test use by Australian GPs, 
patients with TSH, fT3 and fT4 tests will be identified 
from the data. The associations with population charac-
teristics and diagnoses in TSH, fT3 and fT4 testing will 
be investigated and reported by univariate and multivar-
iate logistic regression models, similar to the reporting 
of vitamin D testing outlined previously. In addition to 
the population and general practice demographics, the 
odds of fT3 and fT4 testing by prior TSH test result and 
normal/abnormal TSH test will also be analysed.
The descriptive characteristics for TSH, fT3 and fT4 
tests will be described overall, and by patient's gender, 
age and location, general practice size and year of test. 
The number of fT3 and fT4 tests will be further described 
by TSH testing status: without a prior TSH test, simulta-
neously ordered with a TSH test and following a reported 
TSH test. Where TSH test results are available, fT3 and 
fT4 tests following TSH testing will be further described 
by whether the initial TSH test was normal or abnormal.
sample size considerations
The study will be based on a dynamic cohort, with the 
number of practices, GPs and patients expected to rise. 
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Current estimates suggest that the study will have data 
from 350 general practices. Therefore, it is expected that 
there will be ample scope to detect significant variation 
in practices across patient and general practice demo-
graphic domains.
Patient and public involvement
There was no involvement of patients or the public in this 
study.
dIsCussIon
Pathology tests play an important role in general practice. 
There are guidelines outlining best practice for utilising 
tests, although the role of these guidelines in decision 
making is not well established.
A limitation of using EHRs is that recording of clinical 
data is not always well-standardised, resulting in varia-
tion and inconsistencies in the information available.31 
Issues may arise due to free-text data with no standard 
formatting and absence of recorded comorbidities and 
diagnoses or missing data,32 which are addressed by prior-
itising standardised terms and adopting stringent criteria 
to define variables. The POLAR program already codes 
and organises significant amounts of extracted data, 
and LOINC and SNOMED, both of which are available, 
provide standardised pathology tests and diagnoses. 
Another limitation of this study is that the study popu-
lation will be drawn from only one region of Australia 
(Victoria), and the results may not be nationally repre-
sentative. One other limitation is related to the indica-
tors being measured. Medications, such as clozapine and 
warfarin, are generally prescribed by specialists who might 
also continually monitor the patient’s status. In such 
cases, observed compliance with guidelines in general 
practice may be low. Furthermore, a patient monitored by 
a general practitioner may have occasional visits to their 
specialist, who may order the tests, rather than the GP.
This research will help define the extent to which 
evidence-based best practice guidelines influence deci-
sion making in general practices. To date, difficulties in 
obtaining patient data from EHR software have hindered 
studying pathology test ordering in general practice. This 
study will be one of the first in Australia to extensively 
investigate the impact of best practice guidelines on GP 
testing patterns. The study can ultimately lead to better 
efficiency in pathology testing and improvements in 
patient outcomes by providing much needed information 
on the adherence of GPs to pathology testing guidelines.
Ethics and dissemination
The data will be de-identified and reported at an aggre-
gate level, and the results will neither identify GPs nor 
patients.
The results of this study will be reported to the Austra-
lian Government’s Department of Health, disseminated 
in peer-reviewed academic journals and presented in 
national and international conferences and industry 
forums. The involvement of the PHNs in the research 
process also allows for the research findings to inform 
their activities at an early stage, reducing the usual 
‘research into practice’ delay.
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